<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <title>Advancing the Development of Therapeutics Through Rare Disease Patient Community Engagement</title>
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <style>
        body { font-family: Arial, sans-serif; max-width: 800px; margin: 0 auto; padding: 20px; }
        h1 { color: #333; }
        .metadata { color: #666; font-size: 0.9em; }
        .summary { margin-top: 20px; line-height: 1.5; }
        .source { margin-top: 20px; }
    </style>
</head>
<body>
    <h1>Advancing the Development of Therapeutics Through Rare Disease Patient Community Engagement</h1>
    <div class="metadata">Published: 2026-02-05 11:18:52</div>
    <div class="summary">The Food and Drug Administration (FDA, the Agency, or we) is announcing the following public meeting entitled "Advancing the Development of Therapeutics Through Rare Disease Patient Community Engagement." Convened by the Duke-Robert J. Margolis, MD Center for Health Policy (Duke-Margolis) in collaboration with FDA and supported by a cooperative agreement between FDA and Duke-Margolis, the workshop will focus on how best to understand patients' experiences living with a rare disease and how to incorporate those experiences, as well as patients' priorities for treatment goals, throughout the drug development process.</div>
    <div class="source">Source: <a href="https://www.federalregister.gov/documents/2023/11/20/2023-25500/advancing-the-development-of-therapeutics-through-rare-disease-patient-community-engagement" target="_blank" rel="noopener noreferrer">https://www.federalregister.gov/documents/2023/11/20/2023-25500/advancing-the-development-of-therapeutics-through-rare-disease-patient-community-engagement</a></div>
</body>
</html>
